

## EarlyCDT-Lung combines early cancer detection with favorable overall performance metrics

	SENS	SPEC	RATE	ACC	FPF	PPV	PPV	RR	DLRp	RF(LF)
<b>ECDT (H)<sup>a</sup></b>	26%	98%	1.2%	97%	2%	0.192	1 in 5	14.1	13.0	16.0x
<b>ECDT (M,H)<sup>a</sup></b>	41%	93%	1.2%	92%	7%	0.097	1 in 10	8.4	5.9	8.1x
<b>ECDT (M)<sup>a</sup></b>	16%	92%	1.2%	91%	8%	0.035	1 in 28	2.1	2.0	2.9x
<b>CT (MAYO)<sup>b</sup></b>	68%	80%	1.2%	80%	20%	0.041	1 in 25	8.5	3.5	3.4x
<b>CT (NLST)<sup>c</sup></b>	94%	73%	1.2%	73%	27%	0.040	1 in 25	42.7	3.4	3.3x
<b>CXR (NLST)<sup>c</sup></b>	60%	94%	1.2%	94%	6%	0.109	1 in 9	21.1	10.1	9.1x
<b>MAMM<sup>d</sup></b>	40%	92%	0.8%	92%	8%	0.039	1 in 26	7.4	5.0	3.2x
<b>PSA<sup>e</sup></b>	33%	86%	2.4%	85%	14%	0.055	1 in 18	2.9	2.4	4.6x

### Definitions:

SENS = Sensitivity

SPEC = Specificity

RATE = Assumed cancer rate (NB: CDT has an additional 50% for look-forward (equivalent to 1.8%))

ACC = Accuracy

FPF = False positive fraction = percentage of people without lung cancer who were test-positive.

PPV = Positive predictive value

RR = Relative risk

DLRp = Positive diagnostic likelihood ratio for calculating post-test risk

RF(LF) = Risk multiplication factor for a baseline risk of 1.2% (and incorporating look-forward).

- 
- <sup>a</sup> Boyle P, Chapman CJ, Holdenrieder S, et al. *Clinical validation of an autoantibody test for lung cancer (2011)*. *Ann Oncol* 22(2):383-389.  
*EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. (2012)* Chapman CJ, Healey GF, Murray A, Boyle P,  
*EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. (2012)* Chapman CJ, Healey GF, Murray A, Boyle P,  
Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, Macdonald IK, Robertson JFR. *Tumor Biol*; 33(5):1319-26.  
Healey GF, Lam S, Boyle P, Hamilton-Fairley G, Peek LJ and Robertson JFR. (2013) *Signal stratification of autoantibody levels in serum  
samples and its application to the early detection of lung cancer. J Thoracic Diseases* 5(5): 618-625.
- <sup>b</sup> Swensen, S.J., Jett, J.R., Hartman, T.E. et al (2003) *Lung Cancer Screening with CT: Mayo Clinic Experience. Radiology* 226: 756-761.  
Swensen, S.J., Jett, J.R., Hartman, T.E. et al (2005) *CT Screening for Lung Cancer: Five-year Prospective Experience. Radiology* 235: 259-265.  
Nawa T, Nakagawa T, Kusano S, Kawasaki Y, Sugawara Y, Nakata H (2002) *Lung cancer screening using low-dose spiral CT: results of  
baseline and 1-year follow-up studies. Chest* 122: 15–20.  
Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M, Yamanda T (2001) *Results of  
three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer* 84: 25–32.
- <sup>c</sup> The National Lung Screening Trial Research Team (2011) *Reduced lung-cancer mortality with low-dose computed tomographic screening. N  
Engl J Med* 365:395-409.  
Aberle, D.R., DeMello, S., Berg, C D et al (2013) *Results of the Two Incidence Screenings in the National Lung Screening Trial. N Engl J Med*  
369:920-931.
- <sup>d</sup> National Cancer Institute. *Breast Cancer Surveillance Consortium: Evaluating Screening Performance in Practice. (2004) NIH Publication No.  
04-5490. Bethesda, MD: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, April 2004.*
- <sup>e</sup> Thompson, I.M., Ankerst, D.P., Chi, L.C. et al (2005) *Operating characteristics of prostate-specific antigen in men with an initial PSA level of  
3.0 ng/ml or lower. JAMA* 294(1):66-70.